G a hematopoietic growth factor that is known to act on neutrophilic progenitors. However, recent reports suggest that G-CSF can also affect more immature hematopoietic progenitors. G-CSF enhances the proliferation of multipotential hematopoietic stem cells and supports the formation of blast colonies in vitro.',* Immediate initiation of G-CSF treatment after lethal irradiation gives a higher survival rate than late initiation in dogs. 3 In addition, G-CSF has been shown to increase the number of colony-forming unitsspleen (CFU-S) in mice. 4 These findings suggest that G-CSF has important roles in the early stages of hematopoiesis, but its details and mechanisms of action remain uncertain.
Some methods to detect pre-CFU-S cells have been recently presented. When conventional CFU-S assays was performed along sequential bone marrow transplantation (BMT), CFU-S in the first BMT graft showed characters different from that in the second BMT graft. Hodgson et a1 showed differences in the sensitivity to 5-fluorouracil (5-FU); which eliminates cycling cells including committed progenitors, while sparing early multipotential stem cells. Ploemacher et a17 indicated differences in mitochondrial rhodamin-123 uptake in the CFU-S assay.'.' These differences show that, at the time of the first BMT, CFU-S cells in the second BMT graft are more immature than CFU-S cells in the first BMT graft and, so, are comparable to pre-CFU-S cells. Other evidence also shows the existence of more primitive hematopoietic stem cells than CFU-S by a viewpoint of long-term BM reconstit~tion. ~~~ In this report we examine the in vivo effects of G-CSF on murine hematopoietic cells. To investigate the actions of G-CSF on primitive stem cells, we administered G-CSF immediately after BMT. In addition, 5-FU-treated BM was also used as BMT grafts to enrich these hematopoietic stem cells. Using a murine sequential BMT system, we showed that myeloid cells and pre-CFU-S, but not spleen colonies, were increased by G-CSF administration. The mechanisms of these effects of G-CSF are discussed in this report. In addition, we investigated the effect of G-CSF on the t o be derived from the first donors. G-CSF did not increase the peripheral white blood cell count significantly, but did increase the number of immature myeloid cells and granulocyte-macrophage colony-forming cells in the BM. The number of erythroid cells in the BM was initially suppressed and then increased by G-CSF treatment. In addition, the pre-CFU-S assay showed an increase in pre-CFU-S cells due t o G-CSF administration. The number of spleen colonies of first BMT recipients did not increase, but a higher percentage of them were committed t o a certain lineage by G-CSF treatment. These findings suggest that G-CSF has important roles in the early stages of hematopoiesis.
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differentiation of primitive stem cells by the histologic examination of spleen colonies.
MATERIALS AND METHODS
Mice and 5-FU treatment. BDF, mice aged 8 to 11 weeks were purchased from Japan SLC (Shizuoka, Japan) and maintained under laminar air flow conditions with the acidified drinking water. To prepare BM treated with 5-FU (Hoffman La Roche, Basel, Switzerland), mice were injected intravenously with 5-FU (150 mgikg) and then killed 4 days later. This 5-FU-treated BM (5-FUBM) or untreated normal BM was used as the first graft for BMT. From four to nine mice were examined for each set of experimental conditions. Spleen colonies or CFU-S were assayed by the intravenous injection of BM suspension (1 x laS nucleated cells) on day 0 into irradiated (9.2 Gy) syngeneic BDF, mice. On days 8 and 12, the nodules that developed on the spleen surface were counted after fixation. Irradiated mice without BM injection were confirmed to develop no spleen colonies.
Highly purified recombinant human G-CSF was provided by Kirin Brewery Co Ltd (Tokyo, Japan); the specific activity was 1 x 10' Uimg protein. G-CSF dissolved in phosphate-buffered saline (PBS) was injected subcutaneously once a day on days 0 to 4 (12 For personal use only. on October 30, 2017. by guest www.bloodjournal.org From injections at 24-hour intervals) after the first BMT at a dose of 2 Fghouseid. As a control, PBS alone was administered.
Repeated BMT was performed on day 12 after the first BMT. Femoral BM cells were collected from the recipients of the first BMT and 1 x lo6 nucleated cells from normal BM recipients or 2 X lo5 cells from 5-FUBM recipients were transplanted to each irradiated (9.2 Gy) second recipient mouse. After fixation, spleen colonies were counted and analyzed for their origin on days 8 and 12 after repeated BMT.
Blood samples were drawn from the tail vein and the white blood cell count (WBC) was determined on days 6 and 11 after the first BMT. The femoral BM nucleated cell count (NCC), the differential count, and the assay of granulocyte-macrophage colony-forming cells (GM-CFC) were performed on days 8 and 12 after the first BMT. The WBC and NCC were determined using Turk's solution and the counting plate. Differential counts were performed on cytospin preparations (obtained using a cytocentrifuge from Shandon Southern Instruments Inc, Sewickley, PA) stained with May-Griinwald-Giemsa solution.
Quantification of GM-CFC was performed using a semisolid culture system as described previously.' One milliliter of culture medium in a 35-mm dish contained 1 x lo4 BM nucleated cells, 100 UimL of murine recombinant interleukin-3 (IL-3; generously provided by Dr Ihle, National Cancer Institute, Frederick, MD), 2 UimL of murine recombinant erythropoietin (Epo; generously provided by Chugai Pharmaceutical Company, Tokyo, Japan), 1.2% methylcellulose (Aldrich Chemical Co, Milwaukee, WI), 30% fetal calf serum (Flow Laboratories, North Ryde, Australia), 1% deionized bovine serum albumin (Sigma Chemical Co, St Louis, MO), 0.1 mmol/L mercaptoethanol (Sigma), and a-medium. Cultures were incubated at 37°C in a humidified atmosphere of 5% CO, in air. The colonies were counted by light microscopy 7 days after culture started, and two to four dishes were used to investigate each set of experimental conditions. GM-CFCderived colonies (GM colonies) were identified morphologically, and in some cases the identification was confirmed by collecting the colonies and making cytospin preparations.
Analysis of spleen colonies by polymerase chain reaction (PCR). Spleens were fixed in 90% ethanolI0 and 10% PBS. Then a small tissue fragment (about 0.3 mg) was enucleated from the center of each spleen colony. After washing once by distilled water, the fragment was digested in 200 FL containing 500 pg/mL proteinase K (Boeringer Mannheim Biochemica, Mannheim, Germany), 50 mmol/L Tris-chloride (pH 8.5), 1 mmol/L EDTA, and 0.5% Tween 20 at 37°C overnight with shaking. Then the sample was incubated at 95°C for 10 minutes and 2 FL of it was subjected to PCR amplification (94°C for 1 minute, 55°C for 2 minutes, and 72°C for 3 minutes for 40 cycles), using 2.5 units Ampli Taq (Perkin Elmer Sequen6ial BMT.
Blood and BM examination.

Assays of GM-CFC.
Cetus, Norwalk, CT), 100 ng each primer, and 100 pmol/L each dNTP (Boeringer) in a final reaction volume of 50 pL buffer recommended by the manufacturer (Cetus). For amplification of Y-chromosome-specific sequence (candidate for testis-determining gene),".l2 the sequence of the sense primer was 5'-GACTGGT-GACAATTGTCTAG-3' and the antisense primer sequence was 5'-TAAAATGCCACTCCTCTGTG-3'. For amplification of fl-actin s e q~e n c e , ' '~~~ the sense and antisense primer sequences were 5'-GTACCACAGGCATTGTGATG-3' and 5'-GCAACATAG-CACAGCITCTC-3', respectively. Amplified products were electrophoresed on a 3% agarose and stained by ethidium bromide.
Spleens were fixed in Bouin's solution and embedded in paraffin, and sequential sections were prepared for light microscopic observation by conventional methods. Spleen colonies were classified morphologically into erythroid, granulocyticimonocytic, or mixed colonies. The total number of colonies per spleen determined by this method was almost the same as that determined by surface observation of the spleen. Two or three spleens were investigated for each set of experimental conditions.
Histologic analysis of spleen colonies.
RESULTS
Effects of G-CSF on the WBC and BM. In both normal BM and 5-FUBM recipients, the peripheral WBC showed no significant difference between G-CSF-treated and control mice, but the femoral BM NCC and the GM-CFC were significantly increased in G-CSF-treated mice on days 8 and 12 (except for the NCC of 5-FUBM recipients on day 8). The GM-CFC increase in numbers was 1.5 to 17 times and the increase was larger than that of the NCC (Table 1) .
Differential counts of the BM showed that the increase in the NCC induced by G-CSF was mainly due to an increase in the number of myeloblasts and neutrophils. Interestingly, on day 8 the erythroblast count was larger in control mice than in G-CSF-treated mice, but on day 12 the reverse was true. These changes were observed in both normal BM and 5-FUBM recipients (Fig 1) .
When the BM cells from day 8 5-FUBM recipients were cultured, the size of GM colonies showed an interesting pattern. Small GM colonies were predominant in G-CSFtreated mice, but large colonies were more common in control mice. The same tendency was also observed in the mice transplanted with untreated grafts, although it was not so distinct (Fig 2) .
We followed several mice for a long time. At 7 weeks For G-CSF treatment the MRAICN-SI values in 5 -N B M recipients were much larger than in normal BM recipients ( Table 2) . As reported this implies that femoral BM CFU-S intrinsically migrated to the splccn and formed dclayed colony thcre, and that sensitivity to 5-FU distinguishes C N -S in thc first BMT graft from C N -S in thc second BMT graft. Thercforc, in this setting. CFU-S in thc fcmoral BM of the first rccipients are comparable with pre-CFU-S at the time of the first BMT, as Hodgson and Bradley mentioned." Thus, the MRAICFU-SI is an appropriatc index for indicating the total number of prc-CFU-S graftcd to the first BMT rccipient.
Efects of G-CSF on spleen colonies and pre-CFU-S.
G-CSF treatment had no cffect on the number of spleen colonies of the first recipicnts. In contrast, G-CSF treatment of normal BM or 5-FUBM recipients caused spleen colonies in thc second recipients to incrcase from 2.0 to 5.6 timcs on both day 8 and day 12 after BMT. In addition, G-CSF incrcascd the MRA(CFU-S] from 5.6 to 11.9 times in normal BM rccipients and from 2.8 to 3.6 times in the 5-FUBM recipients (Table 2 ). In normal BM recipicnts, G-CSFobviously decreased the percentage of mixed spleen colonies on both day 8 and day 12 observations. Erythroid colonics showed a tendency to incrcasc following G-CSF administration ( Origin of each spleen colony in secondary recipients. To determine whether each spleen colony of secondary recipients is derived from the first donor or the first recipient, we tried to amplify Y-chromosome-specific sequence and, as a positive control, p-actin sequence using PCR.
To check a sensitivity of this system, samples from a male-derived colony and a female-derived colony were mixed in various ratios and subjected to PCR. A 10% male and 90% female sample showed a faint Y-chromosomespecific band compared with a 100% male sample. In a 1% male and 99% female sample, no Y-chromosome-specific band was visible, as well as in a 100% female sample. For a control study, mixture of male and female BM cells (ratio is 1:l) were transplanted to female mice and each of their spleen colonies was analyzed. Y-chromosome-specific sequence was amplified in half of the colonies, but not in others, as expected (Fig 3A) .
For this sex-discriminating experiment, male mice were used for the first BMT donors and female mice were used for the first and second recipients. For each set of experimental conditions, 10 to 20 spleen colonies obtained from two to six second recipients were analyzed. As a result, the Y-chromosome-specific sequence was amplified in each of 85% to 93% of spleen colonies in secondary recipients of normal BM. No significant difference was observed between G-CSF treatment and nontreatment groups (Fig 3B) . These results indicate that most of the spleen colonies were derived from BM cells of the first donors. It is compatible with our presumption that G-CSF increases pre-CFU-S cells.
DISCUSSION
We investigated the effect of G-CSF on hematopoiesis in mice following BMT. G-CSF expanded the pool of myeloid cells in the BM. It increased the rate of small GM colonies, indicating that differentiation of myeloid-committed cells was induced by G-CSF treatment. The time-course of the effect of G-CSF on erythroid cells is of great interest. G-CSF treatment decreased the number of erythroid cells in the BM on day 8 after BMT, which is compatible with early erythroid suppression by G-CSF." In contrast, more 
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erythroid cells were observed in G-CSF-treated mice on day 12 than in control mice, probably because G-CSF increased the number of erythroid progcnitors.' The lack of a significant WBC increase in response to G-CSF is thought to be due to the G-CSF trcatmcnt bcing too s m n and for too short a time after BMT. G-CSF treatment won after BMT increased the number of prc-CFU-S, but not the number of recipient spleen colonies. On the other hand, Tamura et al have reported that spleen colonies were incrcascd by the G-CSF treatment of donors immediately before transplantation.' The mechanism of thcsc effects of G-CSF on primitive stem cells is uncertain. However, by comparing these observations. we can suggest that G-CSF increascs the number of primitive stem cclls such as CFU-S and prc-CFU-S either when it is administered to mice having normal hematopoietic tissues or after repopulation of the hematopoietic tissues. G-CSF trcatmcnt soon after B M T causcd repopulation of myeloid cells by direct stimulation, but could not increase CFU-S. probably due to a lack of repopulated and functioning hematopoietic tissues. After a certain period of time the at least partly repopulated hematopoietic tissues (stimulated by early G-CSF administration) were assumed to increase the progenitors noticed as pre-CFU-S at the time of the first BMT. Thus, G-CSF appears to act on primitive stem cell proliferation through indirect mechanisms. response to G-CSF treatment was higher in normal BM rccipicnts than in 5-FUBM rccipicnts. When repeated BMT was performed, the increase rate of GM-CFC and mycloid cells in the femoral BM in responsc to G-CSF showed the same tendency on day 12. These observations also suggest repopulated hematopoietic tissues (probably the mycloid fraction) are necessary to allow an increasc of pre-CFU-S by G-CSF treatment. G-CSF decrcascd mixed spleen colonies and increased erythroid colonies (and granulocytic/monocytic colonies on day 12) without increasing the total number of spleen colonies in recipients of the first BMT. The mechanisms causing these effects are unknown. It is generally assumed that primitive stem cells proliferate and differentiate simultaneously.'" If G-CSF shortcns the time taken for the cell cyclc to be completed, thc rate of committed progenitors would increase through an increase in the number of cell cycles in a given time period. However. G-CSF did not have a proliferative effcct on spleen colonies in the first BMT recipicnts, so this mechanism appears to be unlikely.
Another possible mechanism is the earlier commitment of multipotential stem cells, but no change of the time taken for the cell cycle, in response to G-CSF. Earlier commitment is compatible with both a higher rate of committed cells and no proliferation of CFU-S in response to G-CSF.
We developcd a method using PCR to detect the origin For personal use only. on October 30, 2017. by guest www.bloodjournal.org From of each spleen colony. It may be inevitable, when taking colony samples, to also pick up a little surrounding tissue, including donor-derived male cells. However, in our method discrimination of 50% female-derived spleen colonies was successfully performed in a control study in which mixture of male and female BM cells were transplanted. This finding is compatible with a fact that sensitivity for detecting Y-chromosome-specific sequence is not very high, as shown in Fig 3A. This method is useful to demonstrate whether each CFU-S contained in the marrow of first recipients is derived from the endogenous marrow or from the transplanted marrow. Conventional pre-CFU-S assay by sequential BMT was based on a hypothesis that, in the first BMT recipient, CFU-S is derived from the transplanted marrow. We directly showed it is true. In addition, increased numbers of CFU-S by G-CSF treatment were confirmed to originate mostly from the transplanted marrow. This fact supports our conclusion that G-CSF increased pre-CFU-S. But, in most experimental conditions, 7% to 15% of CFU-S originated from the endogenous marrow. We guess that immature fractions of CFU-S derived from the endogenous marrow, which is relatively radiation-resistant, survived.
The timing of the administration of G-CSF to BMT patients is still controversial. Our experimental results suggest that it is reasonable to start G-CSF immediately after BMT. Although G-CSF cannot increase the number of neutrophils in the peripheral blood at that time, it will increase myeloid-committed cells in the hypocellular BM and expand the compartment of primitive stem cells. Clinical studies are necessary to confirm this hypothesis.
